Capecitabine 150mg Tablet, Film Coated
Product Images NDC 72485-204

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine 150mg (NDC 72485-204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72485204 2

Capecitabine Tablets, USP is a cytotoxic agent used for cancer treatment. Each tablet contains 150 mg of Capecitabine. It is important to swallow the tablet whole and not crush or cut it. The usual dosage information is available in the package insert. The tablets should be stored in tight containers at a temperature range of 15°C to 30°C. The tablets are manufactured by Shilpa Medicare Ltd. in India and distributed by Armas Pharmaceuticals Inc. in the USA. The product is available in a blister pack containing 60 tablets.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Disease-free Survival (all Randomized Population)a (Fig 1)

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Overall Survival (all Randomized Population) (Fig 2)

FDA Label Image

Figure 3 Kaplan-meier Curve For Overall Survival Of Pooled Data (studies 1 And 2) (Fig 3)

FDA Label Image

Figure 4 Kaplan-meier Estimates For Time To Disease Progression Capecitabine And Docetaxel Vs Docetaxel (Fig 4)

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Survival Capecitabine And Docetaxel Vs Docetaxel (Fig 5)

This is a table showing estimated probabilities (ranging from 10% to 0%) for different treatment groups. The treatments mentioned are Docetaxel, Capecitabine, and intermittent Widocetaxel for a span of 3 weeks. The dosages mentioned are Docetaxel 100 (mg/sqm/3 weeks), Capecitabine 1250 (mg/sqm twice daily), and intermittent Widocetaxel 75 (mg/sam'3). There is not enough context to determine the purpose of the table or what the probabilities specifically refer to.*

FDA Label Image

Metabolic Pathway (Meta Pathway)

This is a chemical representation of a reaction involving the drug Capecitabine and two enzymes, Carboxylesterase and Cyd deaminase, which are important in the metabolism of the drug. The structure shows the conversion of Capecitabine to §-DFUR and eventually to 5-FU, which is the active form of the drug used in cancer chemotherapy.*

FDA Label Image

Structural Formula (Structural Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.